TOP TEN perturbations for NM_000246 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000246
Selected probe(set): 205101_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000246 (205101_at) across 5339 perturbations tested by GENEVESTIGATOR:

IFN-g study 3 / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):6.534464
Number of Samples:2 / 17
Experimental IFN-g study 3
Bronchial epithelial cells (NHBE) treated with 100 ng/ml recombinant human interferon gamma (IFN-g; vendor: PeproTech / catalog number: 300-02 / catalog name: IFN-?) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):5.241091
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

PI3Kd inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):5.115528
Number of Samples:10 / 10
Experimental PI3Kd inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with delta phosphoinositide 3-kinase (PI3Kd) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

PI3Kg inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):5.0908966
Number of Samples:10 / 10
Experimental PI3Kg inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with gamma phosphoinositide 3-kinase (PI3Kg) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):4.644596
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

GM-CSF study 1 (1ng/ml) / mock treated neutrophils (6h)

Relative Expression (log2-ratio):4.0701447
Number of Samples:10 / 10
Experimental GM-CSF study 1 (1ng/ml)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h.
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

IFN-g study 9 (24h) / untreated epidermal keratinocyte sample

Relative Expression (log2-ratio):3.5709229
Number of Samples:3 / 6
Experimental IFN-g study 9 (24h)
Primary keratinocytes treated with interferon gamma (IFN-g) for 24 hours. Monolayer normal human keratinocyte (NHK) cultures were established and used in the second or third passage. Cultures were grown to 40 or 80% confluence, or maintained to 4 days postconfluency. Cultures were starved of growth factors in nonsupplemented M154 medium for 24 hours, and afterwards stimulated with recombinant human IFN-g for 24 hours.
Control untreated epidermal keratinocyte sample
Untreated primary epidermal keratinocytes. Monolayer normal human keratinocyte (NHK) cultures were established and used in the second or third passage. Cultures were grown to 40 or 80% confluence, or maintained to 4 days postconfluency.

IL-22 study 2 (2d; 200ng/ml) / IFN-g study 8 (2d; 20ng/ml)

Relative Expression (log2-ratio):-3.5686135
Number of Samples:3 / 3
Experimental IL-22 study 2 (2d; 200ng/ml)
Reconstructed human epidermis model (RHE; EpiDermTM/MatTek) incubated in assay media supplemented with 200 ng/ml of interleukin 22 (IL-22) for 2 days. Full-thickness human skin model resembles in vivo epidermal architecture.
Control IFN-g study 8 (2d; 20ng/ml)
Reconstructed human epidermis model (RHE; EpiDermTM/MatTek) incubated in assay media supplemented with 20 ng/ml of interferon gamma (IFN-g) for 2 days. Full-thickness human skin model resembles in vivo epidermal architecture.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):3.553133
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37?C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):3.540224
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.